

## **Highlights from the 8<sup>th</sup> China Pharmacovigilance Conference**

### **Seminar “Monitoring the safety of medicines in the Special Populations”**

Jointly organized by the CDR NMPA and ISoP, ISoP China Chapter and UMC, Seminar 8 of “Monitoring the safety of medicines in the Special Populations”, during the eighth China Pharmacovigilance Conference, was successfully held on 21<sup>st</sup> October 2021. Due to the Coronavirus pandemic, the conference was launched synchronously online. The theme of this session was proposed by CDR and global practices sharing during the seminar will further support the implementation of ICH guidelines and the China GVP, which will be effective on 01 Dec, 2021, will be very beneficial to all, including China regulatory authorities and professionals working in the field of pharmacovigilance.

Dr. Jean-Christophe Delumeau, on behalf of the Executive Committee and Board of ISoP, delivered remarks at the opening ceremony. He emphasized that NMPA, as a member of the Management Committee of ICH, is taking a progressively important role in global pharmacovigilance, and this event, will be a milestone for the international collaboration between ISoP - UMC and CDR NMPA.

The session was co-chaired by Dr. Weiyi Xiong from CDR NMPA and Lingyun Zhou from ISoP China Chapter and Sanofi. In total of 7 experts from abroad and China gave presentation to over two hundred of online participants. They were Dr. Jean-Christophe Delumeau, Ms. Xue Tang from ISoP China Chapter and Pfizer, Dr. Jan Petracek from Institute of Pharmacovigilance, Dr. Phil Tregunno from Medicines and Healthcare products Regulatory Agency (MHRA), Dr. Brian Edwards from Husoteria Ltd., Dr. Qunying Yue from UMC, Professor Li Zhang from Dongfang Hospital Affiliated to Beijing University of Chinese Medicine. They respectively presented “The introduction of ISoP and ISoP China Chapter”, “Pharmacovigilance Certification Process developed in collaboration with ISoP”, “ICSR collection from Apps on portable devices: lessons from 5 years of experience”, “Monitoring the safety of medicines

specific to women of child-bearing age and during pregnancy”, “Monitoring the safety of medicines in children and elderly” and “Monitoring the safety of medicines in patient with chronic kidney disease”.

This successful seminar enhanced the academic exchange in pharmacovigilance among experts and scholars from various countries, and comprehensively presented the latest technology and front-line practice of safety monitoring of medicines in the special populations. It will further improve the level of GVP implementation and pharmacovigilance practice, broaden mind in pharmacovigilance research, and foster the safe and effective use of drug in China.

The seminar ended successfully along with the conclusion from the two Chairs, on behalf of CDR NMPA, ISoP and ISoP China chapter, who delivered a joint remark and expressed gratitude to all experts, online participants, and staff.

(Beijing University of Chinese Medicine, Honghui Wu; Rutgers University, Tianyi Yang)